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In Brief
HIV-1 replication depends on the
integration of the viral genome into the
infected cell DNA. This step can be
modulated by the hRAD51 DNA repair
protein. Pharmacological strategies,
employed by Thierry et al., establish a
direct correlation between the stimulation
of hRAD51 and the inhibition of HIV-1
integration, highlighting the multiple and
opposite regulatory functions of the
recombinase on this important replication
step.
Chemistry & Biology
ArticleDual and Opposite Effects of hRAD51
Chemical Modulation on HIV-1 Integration
Sylvain Thierry,1,10 Mohamed Salah Benleulmi,2,10,11 Ludivine Sinzelle,2 Eloise Thierry,1 Christina Calmels,2,11
Stephane Chaignepain,3 Pierre Waffo-Teguo,4 Jean-Michel Merillon,4 Brian Budke,5 Jean-Max Pasquet,6 Simon Litvak,2
Angela Ciuffi,7 Patrick Sung,8 Philip Connell,5 Ilona Hauber,9,11 Joachim Hauber,9,11 Marie-Line Andreola,2,11
Olivier Delelis,1 and Vincent Parissi2,*
1LBPA, UMR8113, CNRS, ENS-Cachan, 94235 Cachan, France
2MFP, UMR5234, CNRS-Universite´ de Bordeaux, SFR Transbiomed, 33076 Bordeaux, France
3Universite´ de Bordeaux, UMR CNRS 5248 CBMN, 33076 Bordeaux, France
4GESVAB, EA 3675 - UFR Pharmacie, Universite´ de Bordeaux, ISVV, 33076 Bordeaux, France
5Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
6Laboratoire Biothe´rapies des Maladies Ge´ne´tiques et Cancers, INSERM U1035, Universite´ de Bordeaux, 33076 Bordeaux, France
7Institute of Microbiology (IMUL), Lausanne University Hospital, 1011 Lausanne, Switzerland
8Department of Molecular Biophysics & Biochemistry, Yale University School of Medicine, New Haven, CT 06320-8024, USA
9HPI, Leibniz Institute for Experimental Virology, German Center for Infection Research (DZIF), 20251 Hamburg, Germany
10Co-first author
11Associated International Laboratory (LIA) Microbiology and Immunology, CNRS/Universite´ de Bordeaux/Heinrich Pette Institute-Leibniz
Institute for Experimental Virology
*Correspondence: vincent.parissi@reger.u-bordeaux2.fr
http://dx.doi.org/10.1016/j.chembiol.2015.04.020SUMMARY
The cellular DNA repair hRAD51 protein has been
shown to restrict HIV-1 integration both in vitro and
in vivo. To investigate its regulatory functions, we
performed a pharmacological analysis of the retro-
viral integration modulation by hRAD51. We found
that, in vitro, chemical activation of hRAD51 stimu-
lates its integration inhibitory properties, whereas
inhibition of hRAD51 decreases the integration re-
striction, indicating that the modulation of HIV-1
integration depends on the hRAD51 recombinase
activity. Cellular analyses demonstrated that cells
exhibiting high hRAD51 levels prior to de novo infec-
tion are more resistant to integration. On the other
hand, when hRAD51 was activated during integra-
tion, cells were more permissive. Altogether, these
data establish the functional link between hRAD51
activity and HIV-1 integration. Our results highlight
the multiple and opposite effects of the recombinase
during integration and provide new insights into the
cellular regulation of HIV-1 replication.
INTRODUCTION
Retroviral replication requires the integration of the viral cDNA
into the host cell genome, a multistep process catalyzed by
the intasome complex formed between the retroviral integrase
(IN) and the viral DNA (Bowerman et al., 1989; Miller et al.,
1997). After intasome binding to the host chromatin and insertion
of the viral cDNA ends into the target DNA the post-integration
repair (PIR) of the integration locus occurs. This step, probably
catalyzed by host factors, leads to the stable insertion of the viral712 Chemistry & Biology 22, 712–723, June 18, 2015 ª2015 Elseviergenome, the provirus (for reviews, see Hare et al., 2010; Grand-
genett and Korolev, 2010; Cherepanov, 2010). We have
previously shown that hRAD51, belonging to the homologous
recombination DNA repair pathway (HR), could bind HIV-1 IN
(Desfarges et al., 2006) and exert a negative effect on integration
both in vitro and in vivo (Cosnefroy et al., 2012). Indeed, the stim-
ulation of hRAD51 activity by the RAD stimulatory compound 1
(RS-1 [Jayathilaka et al., 2008]), inhibits HIV-1 integration, lead-
ing to a significant decrease of the viral replication (Cosnefroy
et al., 2012). Moreover, hRAD51 has also been shown to activate
the HIV-1 long terminal repeat (LTR) dependent transcription
(Chipitsyna et al., 2006; Kaminski et al., 2014; Rom et al., 2010)
and, thus, to stimulate viral genes expression. These data indi-
cate that hRAD51 plays different roles during the retroviral repli-
cation cycle, which must be taken into account by clinical
approaches. To better understand hRAD51 regulatory functions
we performed a pharmacological analysis of the impact of
hRAD51 chemical modulation on HIV-1 integration. Our results
showed that hRAD51 stimulatory and inhibitory compounds
induced multiple and opposite effects on this specific step of
the retroviral replication cycle. These data indicate that efficient
integration relies on equilibrium between pro- and anti-integra-
tion properties of hRAD51. This suggests that cellular pathways
and/or treatments affecting this equilibrium could differently
affect viral replication and reveals the complex regulatory func-
tions of hRAD51 on integration.
RESULTS
Selection of hRAD51 Chemical Modulators Affecting Its
HIV-1 IN Inhibition Ability
hRAD51 inhibits HIV-1 integration in vitro (Figure S1) and
enhancement of the hRAD51/DNA active nucleofilaments forma-
tion by the RAD51 stimulatory compound 1, RS-1 (chemical
structure shown in Figure 1A) improves the integration inhibitionLtd All rights reserved
Figure 1. Effect of hRAD51 Modulators on HIV-1 Integration
The chemical structure of the stimulatory compoundsRS-1 and P-ter (A) and the inhibitory compounds RI-1 andDIDS, aswell as the sequence of the aptamers (B)
are indicated. Increasing concentrations of wt-hRAD51 were added in a standard concerted integration assay in the presence of 100 mM ATP (without [w/o]
molecule or aptamer), and with 7.5 or 15 mMRS-1 (C), P-ter (D), RI-1 (E), or 0.1, 0.25, or 0.5 mMof A30 (F). The data reported represent the mean values of at least
three independent experiments ± SD (error bars). The activity in the absence of compounds, corresponding to the total amount of donor DNA integrated into the
acceptor plasmid, as detected on agarose gel electrophoresis and shown in Figure S1, was normalized to 100%.by the recombinase both in vitro and in vivo (Cosnefroy et al.,
2012). These data highlighted the role of the nucleocomplex in
the inhibition process. To better characterize the mechanism of
inhibition, we searched for compounds capable of affecting the
hRAD51/DNA binding properties and, thus, the formation of
the active nucleofilament. Stilbenes, like disodium 4,40-diisothio-
cyanatostilbene-2,20-disulfonate (DIDS), having previously been
shown to affect hRAD51 activity (Ishida et al., 2009), we tested
natural stilbenes derivatives recently identified in our laboratory
(Pflieger et al., 2013) in an hRAD51/DNA interaction assay. As re-
ported in Figure S2, most of the 22 molecules tested were found
to inhibit the hRAD51/DNA association, but only one, the E-pter-
ostilbene (P-ter) (chemical structure shown in Figure 1A), stimu-
lated binding. Given that hRAD51 stimulatory compounds are
attractive candidates as antiviral agents (Cosnefroy et al.,
2012), we first focused our interest on the stimulatory molecule.
To verify its possible stimulation effect on hRAD51 strand ex-
change activity, P-ter was assayed in an in vitro recombination
activity. As shown in Figure S3A, P-ter stimulates the recombi-Chemistry & Biology 22,nase activity at least as efficiently as RS-1, (EC50 [half maximal
effective concentration] for P-ter = 19.2 ± 2.4 mM and EC50 for
RS-1 = 25 ± 3 mM).
The hRAD51 stimulatory compounds were then tested on
in vitro hRAD51-mediated inhibition of HIV-1 IN activity using
the concerted integration assay described in Figure S1. As re-
ported in Figure S4A and by Pflieger et al. (2013), P-ter was pre-
viously shown to inhibit HIV-1 IN activity with an IC50 (half
maximal inhibitory concentration) = 47.5 ± 2.5 mM. Since P-ter
showed hRAD51 stimulatory effect between 5 and 20 mM (see
Figure S3) without significantly affecting HIV-1 IN activity, it
was tested at concentrations up to 15 mM on hRAD51-mediated
IN inhibition. As reported in Figure 1C, a strong improvement in
integration restriction was observed in the presence of P-ter,
as observed in the case of RS-1 (Figure 1D). This indicates that
the stimulation of the hRAD51 activity not only by RS-1 but
also by other stimulatory compounds such as P-ter can enhance
the HIV-1 IN inhibition properties of the recombinase. To deter-
mine whether the active hRAD51 nucleofilament could serve as712–723, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 713
a target for modulating hRAD51-mediated inhibition of HIV-1 IN,
we next examined whether inhibition of the recombinase could
also affect its integration restriction properties. Two hRAD51
chemical inhibitors, DIDS (Ishida et al., 2009) and RAD51 inhibi-
tory compound 1 (RI-1) (Budke et al., 2012a, 2012b), and several
DNA aptamers previously selected against hRAD51 (Martinez
et al., 2010; Figure 1B), were tested. These molecules were
assayed on the in vitro hRAD51 recombination activity shown
in Figure S3A. Both RI-1 andDIDS displayed an inhibitory activity
on the strand exchange catalyzed by hRAD51 (IC50 determined
for RI-1 and DIDS were respectively 50 ± 5 mM and 90 ±
2.5 mM, Figure S3B). A47 and A30 aptamers (Martinez et al.,
2010) were also found to strongly inhibit hRAD51 under these
conditions (IC50 for A47 = 75 ± 4 nM and IC50 for A30 = 30 ±
2 nM), while their shortened control versions A47c and A30c
did not (Figure S3C). Among the hRAD51 inhibitory molecules
assayed, DIDS showed a significant IN inhibitory effect (IC50 =
5 ± 2 mM, Figure S4B) and, thus, was excluded from further
analyses. We next compared the effect of RS-1 and P-ter with
that of RI-1 and A30, which showed the best inhibitory effect,
on hRAD51-mediated integration restriction. As reported in Fig-
ures 1E and F, good correlation was observed between hRAD51
activity and IN inhibition. Indeed, all the hRAD51 inhibitors
induced a significant decrease in the hRAD51-mediated integra-
tion inhibition, which is in sharp contrast to the potentiation
observed with the hRAD51 stimulatory compounds RS-1 and
P-ter. No effect of molecules on the IN/hRAD51 interaction
was detected (Figure S5), confirming that the modulation of
hRAD51-mediated inhibition by the drugswasmainly due to their
effect on the active hRAD51 nucleofilaments. This suggested
that modulators of the nucleocomplex could be used as tools
to explore its biological regulatory function in infected cells.
Opposite Effects of hRAD51 Chemical Modulation on
HIV-1 Integration Step in 293T Cells
RS-1 has previously been shown to stimulate hRAD51 activity
both in vitro and in vivo (Jayathilaka et al., 2008) and to inhibit
HIV-1 replication in single- and multiple-round infection assays
performed in different cell types, including primary peripheral
blood mononuclear cells (PBMC) resting cells (Cosnefroy et al.,
2012). To better characterize the mechanism of action of RS-1,
especially at the integration step, we compared it with P-ter
using a typical 293T single-round replication assay, in order to
focus on the early steps of infection. Cytotoxicity measurement
in cells treated with increasing concentrations of drug showed
no significant effect on cells viability (cytotoxic concentration
at which 50% cytotoxicity is observed [CC50] > 250 mM, Figures
S6A and S6B). We next tested the drugs for their effect on
cellular hRAD51-mediated DNA repair activity using a typical
cisplatin resistance assay in a non-toxic concentration range.
As reported in Figures S7A and S7B, a 24-hr treatment of 293T
cells with either RS-1 or P-ter induced an increase in the cisplatin
resistance, as expected from the stimulation of the active
hRAD51 nucleofilament. To determine the effect of the molecule
on intracellular hRAD51 protein, we performed an immunolocal-
ization analysis of the recombinase. As reported in Figure S7C,
cells treated with either RS-1 or P-ter showed an increased num-
ber of hRAD51 nuclear foci compared with untreated cells.
Quantification of the cytoplasmic and nuclear foci (Figure S7D)714 Chemistry & Biology 22, 712–723, June 18, 2015 ª2015 Elsevierconfirmed that treatment with the hRAD51 stimulatory com-
pounds induced a nuclear relocalization of hRAD51, consistent
with a stimulation of the formation of active nucleofilaments in
the nuclear compartment. Since (1) hRAD51 activity could be
altered during cell cycle and (2) the effect of the compounds
on the viral replication might depend on the alternation of cell
cycle, we analyzed the impact of drug treatments on the cellular
cycle. As reported in Figure S7E, propidium iodide labeling of the
cells showed no significant change in the cell cycle alternation of
the treated versus untreated cells. This allowed further analyzes
of drugs effects on early steps of retroviral replication.
As shown in Figure 2A, a 24-hr treatment of 293T cells with
RS-1 prior to transduction with pNL4.3-based pRRLsin-PGK-
eGFP-WPRE VSV-G pseudotyped viruses induced an inhibition
of transduction efficiency. Quantification of the different viral
DNA populations indicated that this phenotype was due to an in-
hibition of integration, as shown by an increase of the amount of
unintegrated two-LTR DNA circles, and a decrease of the inte-
grated DNA form, while the total DNA amount remained
unchanged (Figure 2B). In contrast, treatments performed 5 hr
after transduction induced an opposite phenotype, showing a
stimulation of the viral replication correlated with an increased
integration. To determine whether this dual effect was specific
to the RS-1 molecule, we tested the newly selected P-ter.
Assays performed on 293T cells transduced with the lentiviral
vector produced results similar to those obtained with RS-1 (Fig-
ures 2C and 2D).
The RI-1 compound, exerting an opposite effect to RS-1 on
hRAD51, was then tested. As reported in Figure S6C, no signif-
icant RI-1 toxicity was observed in a 1–50 mM range, although
a slight decrease in cell viability could be observed at concentra-
tions higher than 50 mM (CC50 = 200 ± 15 mM). A 24-hr pre-treat-
ment of 293T cells with RI-1 was found to induce a decrease in
both the cisplatin resistance (Figure S8A) and the nuclear foci
formation (Figure S8B). These results confirmed that RI-1 could
negatively modulate the hRAD51 DNA repair activity. The drug
was next tested on early steps of retroviral replication. As re-
ported in Figure 3A, a 24-hr pre-treatment led to an increase of
the percentage of eGFP-positive 293T cells transduced with
the lentiviral vector (EC50 = 50 ± 12 mM). Quantification of the viral
DNA species indicated that the phenotype was due to a stimula-
tion of integration, as shown by the significant increase in inte-
grated DNA forms and the decrease of two-LTR circles, the
global viral DNA amount remaining unchanged (Figure 3B). Strik-
ingly, a 5-hr post-transduction treatment with RI-1 induced an
opposite effect. Indeed, the viral replication was inhibited
(EC50 = 50 ± 6 mM), with a decrease in the integrated DNA forms
accompanied by slight increase of the two-LTR circles. In
contrast, a 16-hr post-transduction treatment had no significant
effect on replication.
These results demonstrated that the hRAD51 activity modula-
tion can have opposite effects on integration depending on the
chronology of the treatment. Especially, stimulation of the re-
combinase prior to transduction rendered the cells resistant to
integration, whereas stimulation of hRAD51 after transduction
had a positive effect on integration. Thus, depending on its cat-
alytic status, hRAD51 can either positively or negatively influence
the early steps of HIV-1 replication by acting at the integration
step. In view of these data, one important conclusion is that cellsLtd All rights reserved
Figure 2. Effect of RS-1 and P-ter Treatment on Early Steps of HIV-1 Replication and Viral DNA Populations
Cells were treated for 24 hr prior to, concomitantly, or 5–16 hr after transduction with either RS-1 (A and B) or P-ter (C and D). The eGFP fluorescence was
measured 10 days after transduction by flow cytometry. The percentage of eGFP-positive cells in the absence of compound was normalized to 100% (A and C).
The amount of the total, integrated, and 2-LTR circles viral DNA formswas quantified as described in the Experimental Procedures at a fixed 30 mMconcentration
(effective and non-cytotoxic) of RI-1 or P-ter, under two distinct treatment conditions (early and late). The amount of each viral DNA species produced in the
absence of compound was normalized to 100% (B and D).
Results are the mean of three independent experiments. The p values calculated using Student’s t test are indicated as *p < 0.05, **p < 0.005. w/o, without.with higher hRAD51 intracellular concentrations would be ex-
pected to be more resistant to HIV-1 infection. To verify this
hypothesis, we studied the effect of the hRAD51 intracellular
concentration on integration and viral replication.
Modulation of hRAD51 Expression Affects Both Cellular
DNA Repair Activity and HIV-1 Integration
In order to increase the hRAD51 intracellular content, an
hRAD51-FLAG tagged protein was overexpressed in 293T cells
by transfection with the pcDNA-hRAD51 expression vector.
Expression of the heterologous recombinase was checked by
western blotting using an anti-FLAG antibody (Figure 4A). The
global hRAD51 expression level was evaluated by western blot-
ting using an anti-hRAD51 antibody, allowing detection of both
the expressed and the endogenous hRAD51. Under our ex-
perimental conditions, we reached a 3- to 5-fold increase in
hRAD51expression comparedwith non-transfected cells or cells
transfected with a BAP-FLAG control vector (Figure 4B).
Immunolocalization experiments of the hRAD51-FLAG proteinChemistry & Biology 22,using an anti-FLAG antibody showed the formation of typical
nuclear foci specific of the active DNA repair recombinase, while
theBAP-FLAGcontrol protein showed amore diffuse localization
(Figure 4C). Thiswas confirmed bymeasuring the hRAD51-medi-
atedDNA repair activity throughacisplatin resistanceassay, indi-
cating a significant enhancement of the resistance to cisplatin of
the cells overexpressing hRAD51-FLAG (Figure 4D). Altogether
these data demonstrate that hRAD51-FLAG overexpression
stimulates the intrinsic cellular DNA repair activity.
Early steps of HIV-1 replication were then analyzed in cells
overexpressing hRAD51-FLAG by transduction with pRRLsin-
PGK-eGFP-WPRE VSV-G pseudotyped viruses and measure-
ment of the eGFP expression from the integrated gene. As
reported in Figure 4E, hRAD51-FLAG overexpression induced a
significant 40%–50% inhibition of HIV-1 replication, in contrast
to BAP-FLAG. Under these conditions, no significant change in
the total viral DNAamountwas detected, while a strong decrease
in the integrated DNA forms was observed in addition to an in-
crease of the unintegrated two-LTR circles (Figure 4F). This712–723, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 715
Figure 3. Effect of hRAD51 Inhibitory Compounds RI-1 on Early Steps of HIV-1 Replication
(A) Cells were treated for 24 hr prior to, concomitantly, or 5–16 hr after transduction. eGFP fluorescence was measured 10 days following transduction by flow
cytometry. The percentage of GFP-positive cells obtained in the absence of compound was normalized to 100%.
(B) The effect of RI-1 on viral DNA production wasmeasured by quantifying the total, integrated, and 2-LTR circles viral DNA forms at a fixed 50-mMconcentration
(non-cytotoxic and effective) of RI-1, under two treatment conditions. The proportion of the different DNA species obtained in the absence of compound was
normalized to 100%.
Results are represented as the mean values calculated from three independent experiments. The p values are reported as *p < 0.05, **p < 0.005. w/o, without.confirmed the effect of hRAD51 on the integration step following
nuclear entry of the viral cDNA. To better characterize the rela-
tionship between the intracellular concentration of hRAD51 and
HIV-1 integration efficiency, we tested whether decreasing the
hRAD51 expression level could induce an opposite phenotype.
For this purpose, a pharmacological approach was used to
reduce hRAD51 expression. Imatinib (Figure 5A) was previously
reported to decrease the hRAD51 protein levels and increase
tumor cell radiosensitivity (Russell et al., 2003). In vitro control ex-
periments showed that this compounddid not affectHIV-1 INand
hRAD51 catalytic activities (Figure S9A), validating our approach.
As reported inFigureS9B, treatmentwith imatinib concentrations
above 10 mM led to a significant cellular toxicity (EC50 = 30 ±
8 mM). The effect of the drug on hRAD51 expression was thus
evaluated using concentrations below10mM.Western blot quan-
tifications of hRAD51 expression following imatinib treatment
confirmed that the drug could induce an efficient 40%–50%
decrease 10 hr after treatment, while the initial level of hRAD51
was recovered after 72 hr (Figure 5B). The decrease was also
associated with a reduced hRAD51 DNA repair activity as
measuredby thequantification of cisplatin resistance (Figure 5C).
Based on these data, HIV-1 replication was tested 24 hr after
treatment. As reported in Figure 5D, imatinib treatment 24 hr
before transductionof thecells led toan increase in eGFPexpres-
sion associated with a typical enhancement of the integration
efficiency (Figure 5E). These results demonstrate that an upregu-
lation of hRAD51 expression both stimulates endogenous DNA
repair and induces HIV-1 integration restriction.
hRAD51 Expression and Intracellular Localization Are
Modulated during HIV-1 Early Steps of Replication
To determine whether hRAD51 expression could be modulated
during the viral infection, we transduced 293T cells with
pNL4.3-based pRRLsin-PGK-eGFP-WPRE VSV-G pseudo-716 Chemistry & Biology 22, 712–723, June 18, 2015 ª2015 Elseviertyped vectors and analyzed the hRAD51 protein content of
cellular extracts obtained at different time points after transduc-
tion. As reported in Figure 6A, a decrease in the hRAD51 protein
content was detected 4–12 hr after transduction and an increase
of the protein level was observed 16–24 hr after transduction. In
contrast, the hRAD51 protein amount was found unchanged in
the non-transduced cells. Transcription activity of the RAD51
genes was then analyzed. We used the http://www.peachi.
labtelenti.org web resource allowing the querying of cellular re-
sponses to infection in SupT1 T cells transduced by HIV-based
vectors (Mohammadi et al., 2013). Genes encoding for RAD51
and paralogs were found highly downregulated during the early
steps of infection (0–6 hr) and upregulated during the integration
step (8–16 hr) in contrast to other RAD genes such as RAD18 or
RAD54 (Figure S10). These data indicate that hRAD51 expres-
sion is modulated during the early steps of replication at the tran-
scription level. We next analyzed the cellular behavior of the
endogenous hRAD51 by immunofluorescence staining of trans-
duced cells at different time points. As shown in Figure 6B, a
modulation of the cellular localization could also be detected
during the early stages of the replication. Indeed, while
hRAD51 foci were found equally distributed in both cytoplasm
and nuclear compartment during the 0–8 hr after transduction,
a strong relocalization of the recombinase was detected during
the 12–24 hr after transduction. No significant change was
observed in the non-transduced cells (Figure S11). Conse-
quently, all these data strongly suggest that viral infection mod-
ulates both hRAD51 expression and intracellular localization
during the early stages of replication.
DISCUSSION
Retroviral integration introduces cuts in the host cell DNA that
can be considered as potential mutagenic events by the cellularLtd All rights reserved
Figure 4. Effect of hRAD51 Overexpression on Endogenous DNA Repair and Early Steps of HIV-1 Replication and Viral DNA Productions
(A) The expression of hRAD51-FLAG or BAP-FLAG in 293T cells was checked 48 hr after transfection by western blotting using anti-FLAG antibodies (lane 1,
protein extract from cells expressing hRAD51-FLAG; lane 2, protein extract from cells expressing BAP-FLAG).
(B) The global hRAD51 level was determined in cells transfected with the hRAD51-FLAG (hRAD51) and BAP-FLAG (BAP) expression vectors in parallel to un-
transfected control cells (without [w/o] transfection), by western blotting using anti-hRAD51 antibodies. The amounts of protein loaded were normalized to the
endogenous actin protein revealed by western blotting using an anti-actin antibody.
(C) The cellular distribution of the overexpressed proteins was determined by immunolocalization using an anti-FLAG antibody.
(D) The hRAD51 activity was determined under each condition by a cisplatin resistance assay as described in the Experimental Procedures. The cells were
transduced 48 hr after transfection with the hRAD51 or BAP expression plasmids.
(E) HIV-1 replication was evaluated from fluorescence measurement 10 days after transduction by flow cytometry. The percentage of untransfected eGFP-
positive cells was normalized to 100%.
(F) The amount of total, integrated, and 2-LTR circles viral DNAs was measured by qPCR as described in the Experimental Procedures. The proportion of the
different viral DNA species produced in untransfected control cells was normalized to 100%.
Results are represented as the mean values calculated from three independent experiments. The p values are shown as *p < 0.05, **p < 0.005.DNA repair machinery. Furthermore, the incoming intasome con-
taining blunt-ended viral DNA can also be recognized as a dou-
ble-strand break (DSB) by the homologous repair (HR) pathway
in the infected cells. This is supported by the formation of active
hRAD51 nucleofilaments on viral DNA in presence of IN as de-
tected in previous electron microscopy analyses (Rom et al.,
2010). HR hRAD51 protein bindsHIV-1 IN and restricts its activity
both in vitro and in vivo through a DNA/IN dissociation process
dependent on the formation of active hRAD51 nucleofilaments
(Desfarges et al., 2006; Cosnefroy et al., 2012). The stimulation
of hRAD51-mediated inhibition of HIV-1 integration, by using
drugs like RS-1, for example, results in the suppression of viralChemistry & Biology 22,replication in different cell types, including primary resting
PBMCs (Cosnefroy et al., 2012). In addition, hRAD51 has been
shown to stimulate the expression of proviral genes by
enhancing LTR-dependent transcription (Kaminski et al., 2014;
Rom et al., 2010). These data indicate that efficient HIV-1 infec-
tion relies on an optimal intracellular activity of hRAD51. Here,
using a pharmacological approach allowing modulation of
hRAD51 activity, we provide a comprehensive analysis of the
mechanisms involved in the regulation of HIV-1 integration.
We first selected molecules capable of modulating the
hRAD51-mediated inhibition of HIV-1 IN. Several previously
described hRAD51 inhibitors such as RI-1 and A30 (Budke712–723, June 18, 2015 ª2015 Elsevier Ltd All rights reserved 717
Figure 5. Effect of Imatinib Treatment on hRAD51 Expression Levels, Endogenous DNA Repair and Early Steps of HIV-1 Replication
(A) The chemical structure of imatinib.
(B) The total protein fraction was extracted 6–72 hr following treatment with imatinib. The hRAD51 protein levels were determined from western blot analyses
using an anti-hRAD51 antibody. The amount of hRAD51 protein present in untreated cells was normalized to 100%.
(C) The ability of imatinib to affect cisplatin resistance was checked in a standard survival analysis performed after 24 hr of treatment with increasing concen-
trations of the compound. Survival was expressed as the ratio of absorbance at 492 nM (Synergy [BioTek] plate reader) of cisplatin-treated cells (pre-incubated
with the compound or not) relative to untreated cells. Results represent the means of at least three independent experiments ± SD (error bars).
(D) The effect of imatinib on early steps of HIV-1 replication was analyzed following a 24-hr treatment of the cells before transduction with the lentiviral vector.
eGFP fluorescence was measured 10 days after transduction by flow cytometry. The percentage of eGFP-positive cells in the absence of compound was
normalized to 100%.
(E) The amount of total, integrated, and 2-LTR circles viral DNA forms was quantified at a fixed 10 mM concentration (effective and non-cytotoxic) of imatinib. The
amount of each viral DNA species produced in the absence of compound was normalized to 100%. The results are presented as the mean of three independent
experiments. *p < 0.05.et al., 2012b; Martinez et al., 2010) were found to alleviate the
in vitro integration restriction properties of the recombinase.
On the contrary, hRAD51 stimulatory compounds, like the previ-
ously reported RS-1 (Jayathilaka et al., 2008) and the newly
selected E-pterostilbene purified from grape wine (Pflieger
et al., 2013), promoted the hRAD51-induced restriction of
HIV-1 integration. These results, summarized in Figure S12,
show a strong correlation between the recombination activity
of hRAD51 and its ability to inhibit IN. Furthermore, none of the
drugs affected the IN/hRAD51 association. These data strongly
suggest that integration restriction relies on the formation of
active hRAD51 nucleofilaments. This nucleocomplex could,
thus, constitute a valuable pharmacological target for strategies
aiming to modulate HIV-1 replication by targeting the integration718 Chemistry & Biology 22, 712–723, June 18, 2015 ª2015 Elsevierstep. In addition, to provide new information about the hRAD51-
induced integration restriction, these molecules could also serve
as tools to further explore the role of hRAD51 in proviral LTR-
driven gene expression.
The use of chemical modulators produced differential and
opposite effects on both HIV-1 integration and replication de-
pending on the time of treatment (data summarized in Fig-
ure S13). Early stimulation of hRAD51 (treatment at 24 hr before
transduction) negatively impacted integration and replication,
whereas late stimulation (i.e. 5 hr after transduction) had an
opposite effect. Likewise, early inhibition of the hRAD51-medi-
ated recombination induced a stimulation of integration and
replication, in contrast to what was observed using a 5-hr
post-transduction treatment, which led to a significant decreaseLtd All rights reserved
Figure 6. Expression and Intracellular Local-
ization of hRAD51 during the Early Steps of
HIV-1 Replication in 293T Cells
(A) Proteins were extracted at different time points
(0–32 hr) after 293T cell transduction with pNL4.3-
based pRRLsin-PGK-eGFP-WPRE VSV-G pseu-
dotyped viruses and the hRAD51 expression level
was analyzed by western blot. The amount of
hRAD51 was normalized to the amount of actin
detected by western blot. The quantity of hRAD51
detected at time point = 0 was then normalized to
100%. The results are represented as the mean of
three independent experiments. Data obtained
without transduction (mock) are also reported.
(B) The cellular distribution of hRAD51 was deter-
mined by immunolocalization at different time
points after 297T cell transduction using an anti-
hRAD51 antibody. Results are reported as the
mean number ± SD of cytoplasmic and nuclear
foci observed under each condition for at least
50 cells. A typical picture of hRAD51 intracellular
localization is also provided for several time periods
corresponding to the early and late steps of
integration.of the replication due to an integration defect. The integration
window has been previously determined and is broadly admitted
to take place between 6 and 20 hr after infection in T cell lines
(Mohammadi et al., 2013; Manic et al., 2013). Since the expres-
sion of the reporter gene used in our lentiviral vectors is LTR in-
dependent, our data indicate that hRAD51 plays distinct and
opposite functions in the regulation of HIV-1 integration, display-
ing an early restrictive effect and a late stimulatory effect (sum-
mary in Figure 7).
The integration restriction activity of hRAD51 is likely to be
related to the previously reported IN/viral cDNA dissociation
mechanism through the formation of the hRAD51/DNA nucleofi-
laments. Indeed, the incoming preintegration complexes (PICs)
may be recognized early by hRAD51, thanks to (1) the affinity
of the recombinase for both IN and the viral cDNA (Desfarges
et al., 2006; Cosnefroy et al., 2012) and (2) the recognition of
the blunt-ended retroviral genome as a DSB, as expected from
its intrinsic DNA repair properties (Cosnefroy et al., 2012). This
is also supported by our biochemical data showing that
hRAD51 more efficiently targets the HIV-1 IN/DNA complex
(see Figure S1B) and by the systematic correlations observed
between HIV-1 integration restriction and hRAD51-mediated
DNA repair activity, in vivo (see Figures S13 and S14). Moreover,
under the same experimental conditions, integration inhibitionChemistry & Biology 22, 712–723, June 18, 2015was consistently found associated with
an increase of the amount of two-LTR cir-
cles assumed to be formed in the nucleus.
This indicates an effect downstream of the
nuclear import of the PIC. hRAD51 target-
ing toward the incoming intasome in the
nucleus could prevent the latter from
reaching the integration locus. This hy-
pothesis is also strongly supported by
the treatment-dependent cellular localiza-
tion of hRAD51, as stimulatory com-pounds were found to promote the nuclear translocation of the
recombinase in contrast to hRAD51 inhibitors (see Figure S7C
and S7D; Figure S8B).
Themechanisms of regulation brought into play in cells treated
5 hr after transduction remain to be fully determined. Neverthe-
less, the data obtained using stimulatory and inhibitory com-
pounds strongly support that they target a pro-integrative
function of the recombinase. Since hRAD51 is the main actor
of the homologous DNA repair pathway, one relevant hypothesis
may be that the recombinase acts at the step of PIR by promot-
ing it. This relationship between retroviral integration and DNA
repair has been previously proposed (Kilzer et al., 2003). The
PIR and the involvement of hRAD51 during this process are
currently under study in our laboratory. Especially, the possible
role of the nucleofilament-mediated dissociation of HIV-1 IN
following strand transfer, which has previously been shown to
be required for efficient DNA repair of the integration locus
(Yoder and Bushman, 2000; Brin et al., 2000), must be investi-
gated. Indeed, this enhancement of the PIR by hRAD51 could
be associated to the previously reported function of the recom-
binase in the LTR-driven transcription of the provirus (Chipitsyna
et al., 2006; Kaminski et al., 2014; Rom et al., 2010) and/or to the
chromatin remodeling properties of the recombinase (Dupaigne
et al., 2008). Indeed, nucleosomal DNA remodeling at theª2015 Elsevier Ltd All rights reserved 719
Figure 7. Influence of hRAD51 and Its Mod-
ulation on HIV-1 Integration
hRAD51 recombinase activity, namely the forma-
tion of the active nucleofilament, plays a negative
regulatory role on the steps following PIC nuclear
import and preceding strand transfer catalysis, and
a positive regulatory role during the steps subse-
quent to integration, including DNA repair. Chem-
ical modulators targeting these dual effects can
exert opposite effects on HIV-1 integration, and
hence on viral replication.integration site has been proposed to be important for efficient
integration (Lesbats et al., 2011a, 2011b). This is supported
by the relocalization of endogenous hRAD51 protein during
the integration step in the nuclear compartment where PIR
must occur (Figure 6B). Biochemical data showing that
hRAD51 can promote the in vitro DNA repair step catalyzed
by human flap endonuclease 1 also support this hypothesis
(data not shown). However, the role of hRAD51 during the DNA
repair of the gapped intermediates remains to be fully investi-
gated and, to this purpose, the chemical compounds reported
in this work could constitute useful tools for further studies of
this process.
Our data confirm that cellular DNA repair machineries can
play multiple roles by restricting retroviral integration and/or
directly participating in the stability of the integrated DNA. For
an optimal viral replication equilibrium between these, opposite
effect must be reached. Our results indicate that this can be
accomplished by regulation of hRAD51 endogenous expres-
sion levels and localization during viral replication (cf. Figure 6).
This suggests that the expression of the anti-integration prop-
erty of hRAD51 during the early steps of replication (0–6 hr)
can be overcome by the decrease of the protein level, and
hRAD51 activity. Indeed, this is expected to limit the integration
inhibition by the recombinase as observed during chemical
treatments with imatinib decreasing the hRAD51 expression
and promoting the integration (Figure 5). This would allow the
virus to reach a suitable level of efficient integration for opti-
mized replication. In addition, to highlight the biological regula-
tory functions of hRAD51 on HIV-1 integration, our data also
provide new insights on the possible use of chemical com-
pounds targeting hRAD51 as antiviral agents restricting HIV-1
replication by modulating the recombinase activity in infected
cells. Interestingly, the drug concentrations used in our work
are fully compatible with the concentrations used in cellular
or clinical studies (Jayathilaka et al., 2008; Russell et al.,
2003). However, our data indicate that further development
toward antiviral compounds will be a difficult task due to the720 Chemistry & Biology 22, 712–723, June 18, 2015 ª2015 Elsevier Ltd All rights reserveddual regulatory function of the recombi-
nase described in this work, as well as
the possible secondary effects due to
an alteration of DNA repair processes in
the infected cells. Nevertheless, we
have previously shown that strategies
aiming to stimulate hRAD51 activity in a
multiple-round infection system, as in
PBMCs, could be successful. Indeed,stimulation of the hRAD51-mediated DNA repair pathway prior
to HIV-1 infection has shown a protective effect against viral
replication without affecting the viability of the cells (Cosnefroy
et al., 2012). Consequently, based on our results, we can spec-
ulate that early stimulation of hRAD51 activity (by overexpres-
sion or allosteric stimulation) would be efficient against viral
replication and effort should be made toward this strategy. In
addition, compounds targeting the hRAD51 DNA repair activity
are potential anti-cancer drugs and some anti-cancer mole-
cules, such as imatinib, which is already used in clinic, have
an impact on hRAD51 expression. Importantly, these effects
are observed using a micromolar range of drug amounts close
to the plasmatic concentrations used in clinic. Consequently,
another important conclusion to be drawn from our finding is
that great care should be taken when treating HIV-1-infected
patients with hRAD51 modulators, as a burst in viral replication
may be expected to occur through LTR-dependent proviral
transcription and/or under conditions favoring hRAD51 pro-
integration functions.
SIGNIFICANCE
Regulation of HIV-1 integration is crucial for efficient viral
replication and, thus, constitutes an attractive target for
antiviral therapies. The hRAD51 DNA repair protein has
been shown tomodulate integration activity. A better under-
standing of the regulation properties of this recombinase is
essential for therapeutic approaches targeting DNA repair.
The work presented here establishes the link between
hRAD51 activity and HIV-1 integration efficiency in infected
cells. Indeed, the pharmacological analyses performed
demonstrates that hRAD51 plays dual and opposite roles
in the regulation of integration, indicating that efficient HIV
replication depends on an optimal intracellular level of
hRAD51. In addition, to provide new virus/host interactions,
our data may have important implications in the develop-
ment of antiviral strategies based on the modulation of the
activity of the cellular DNA repair machinery. Indeed, the
work presented here highlights the different pro- and anti-
integration properties of hRAD51, which must be taken
into consideration for future pharmacological development,
and, importantly, shows how chemical modulation of the
hRAD51 activity can induce opposite effects on viral
replication.
EXPERIMENTAL PROCEDURES
Chemicals, Proteins, and Antibodies
RS-1 and RI-1 were previously selected from a 10,000-compound library
(ChembridgeDIVERSet) screened for their capacity to affect the DNA binding
properties of hRAD51 (Jayathilaka et al., 2008; Budke et al., 2012b). DIDS pre-
viously reported as an hRAD51 inhibitor (Ishida et al., 2009) was purchased
from Sigma. P-ter was extracted from Vitis vinifera leaves (isolation and purifi-
cation protocols described in Pflieger et al., 2013). Imatinib was purchased
from Selleck Chemicals (Euromedex). Aptamers A30 and A47, previously
selected as ligands of hRAD51 (Martinez et al., 2010), and their shortened ver-
sions A30c and A47c were purchased from MWG. Cisplatin was purchased
from Sigma. Recombinant HIV-1 IN was expressed in yeast and purified using
the INHybrid method previously described (Lesbats et al., 2008). Wild-type re-
combinant hRAD51 was produced as described before (Chi et al., 2006).
Monoclonal anti-FLAG and polyclonal anti-hRAD51 antibodies were pur-
chased from Sigma.
In Vitro Enzymatic Assays
HIV-1 concerted integration reactions were performed as described previously
(Lesbats et al., 2008) and in Figure S1. All IN activities were quantified by scan-
ning the bands (half-site plus full-site integration products) following gel elec-
trophoresis and autoradiography, using ImageJ software. hRAD51 activity
was evaluated according to the strand exchange reaction previously reported
(Takizawa et al., 2004) and adapted to our concerted integration conditions
(see Figure S3). Strand exchange products were quantified following autoradi-
ography of the gel, using ImageJ software. Measurements of the hRAD51 DNA
binding activity was performed as previously described with slight modifica-
tions (Budke et al., 2012b) (see Figure S2).
Transfection Assay
293T cells were grown in DMEMGlutamax medium (Invitrogen) supplemented
with 10% heat-inactivated fetal calf serum (FCS; Invitrogen) and 50 mg/ml
gentamicin. The cells were seeded into 48-well plates 24 hr before transfec-
tion. Fifteen thousand cells were transfected with 1 mg of either p3X-FLAG-
CMV-hRAD51 (hRAD51) expression vector or p3X-FLAG-CMV-7-BAP (BAP)
expression control plasmid using lipofectamine 2000 (Invitrogen). DMEM con-
taining 20% of FCS was added 4 hr after transfection. Cells were incubated at
37C in a humidified atmosphere containing 5% CO2 for 48 hr and then lysed
with SDS loading buffer. Extracted proteins were separated on 12% SDS-
PAGE and analyzed by western blotting.
Transduction of 293T Cells
293T cells were plated in 48-multiwell plates at 50,000 cells/well using 400 ml of
DMEM (Invitrogen) containing 10% (v/v) FCS and 50 mg/ml of gentamycin
(Invitrogen). Infection was assayed using pNL4.3-based pRRLsin-PGK-
eGFP-WPRE VSV-G pseudotyped lentiviruses produced as described in
Richard et al. (2001). After three washes with PBS (140 mM NaCl, 3 mM KCl,
8 mM Na2HPO4, 1.5 mM KH2PO4 [pH 7.4]), the cells were transduced with
the lentiviral vector at an optimized MOI of 1, in a final volume of 400 ml (under
these conditions, 25%–35% of the cells contained one integrated viral cDNA
copy). After 10 days, the cells were washed twice with PBS, treated with
trypsin for 5 min at room temperature, and centrifuged for 2 min at
2000 rpm. The pellet was washed twice with PBS and resuspended in 200 ml
of PBS/200 mM EDTA. Fluorescence was quantified using 10,000 cells on a
FACS Calibur (Beckton-Dickinson). Plots were analyzed using the FCS
express v3.00.0103. Data are presented as the percentage of cells showing
a significant level of fluorescence or as the fluorescence intensity calculated
by the X-median fluorescence intensity of all cells.Chemistry & Biology 22,Intracellular hRAD51 Immunolocalization
293T cells transfected with the p3X-FLAG-CMV-hRAD51 (hRAD51) or p3X-
FLAG-CMV-7-BAP (BAP) expression vectors, or treated with one of our com-
pounds, were washed three times with PBS and incubated for 10 min in
fixation buffer containing 2% formaldehyde. After two washes, the cells
were incubated for 5 min in permeabilization buffer (PBS supplemented
with 0.4% saponin and 0.1% Triton X-100). The cells were washed with
PBS supplemented with 0.1% saponin and incubated for 1 hr at room tem-
perature in blocking buffer (PBS 0.1%, 1% BSA, 2% FCS). The cells were
incubated with the primary antibody overnight at 4C. After three washes
with PBS, the secondary antibody coupled to Alexa 440 was added and
the cells were further incubated for 1 hr at 37C. DAPI was added at a final
concentration of 1 mg/ml for 10 min at room temperature. The cells were then
washed four times with PBS before fluorescence microscopy analysis. A
similar procedure was used for hRAD51 intracellular localization analysis in
293T cells transduced with pRRLsin-PGK-eGFP-WPRE VSV-G pseudotyped
lentiviruses.
Cytotoxicity and Cell Cycle Measurements
The cellular cytotoxicity of the compounds was determined by measuring
the survival of cells treated with increasing concentrations of molecules for
2 days with a standard MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay (PromegaCellTiter 96
AQueous One Solution Cell Proliferation Assay). Analyses of the cell cycle
were performed using a propidium iodide flow cytometry kit from Abcam
following the manufacturer’s instructions.
Quantification of Cisplatin Resistance
The effect of protein overexpression and chemical treatment on hRAD51-
mediated homologous recombination was assessed using the standard
cisplatin resistance assay described previously (Jayathilaka et al., 2008).
Quantification of HIV-1 DNA Species
The cells were harvested 8, 24, and 48 hr after infection by centrifugation,
and aliquots of 2 3 106 to 6 3 106 cells were kept frozen at 80C until
analysis. Total DNA (including integrated and episomal HIV-1 DNA) was
extracted using the QiAmp blood DNA mini kit (Qiagen) according to the
manufacturer’s instructions and eluted in 50 ml of elution buffer. Quantifica-
tion of the viral DNA species was performed using the conditions and primers
described in Brussel and Sonigo (2003). The total HIV-1 DNA was amplified
by quantitative real-time PCR using a LightCycler instrument (Roche
Diagnostics). Quantifications of total HIV-1 DNA, including 2-LTR circles
and integrated HIV-1 cDNA, were performed by qPCR on a LightCycler
instrument using the fit point method provided in the LightCycler quantifica-
tion software, version 4.1 as previously described (Zamborlini et al., 2011).
The copy numbers of 2-LTR circles and total viral DNA were determined
with reference to a standard curve prepared by amplification of quantities
ranging from 10 3 106 to 1 3 106 copies of plasmid comprising the HIVLAI
2-LTR junction (Manic et al., 2013). The integrated HIV-1 cDNA copy number
was determined with reference to a standard curve generated by the
concomitant two-stage PCR amplification of serial dilutions of an integrated
HIV-1 DNA standard from Hela-R7 Neocells (Munir et al., 2013). Cell equiva-
lents were calculated according to amplification of the b-globin gene (two
copies per diploid cell) with commercially available materials (Control Kit
DNA; Roche Diagnostics). 2-LTR circles and total and integrated HIV-1
DNA levels were determined as copy numbers per 106 cells. Two-LTR circles
and integrated cDNA were also expressed as a percentage of the total
viral DNA.
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